Abstract: A solid composition comprising the following components (A) and (B): (A) from 20 to 65 mass % of a fat globule membrane component; and (B) from 0.2 to 4 mass % of a water-soluble dietary fiber having a weight average molecular weight of 10,000 or more.

Abstract: A solid composition comprising the following components (A) and (B): (A) from 20 to 55 mass % of a fat globule membrane component; and (B) from 0.2 to 4 mass % of a water-soluble dietary fiber having a weight average molecular weight of 10,000 or more.

Abstract: A solid supplement comprising the following components (A) and (B): (A) sphingomyelin in an amount of from 0.15 to 7% by mass; and (B) phosphatidyl inositol or a salt thereof, wherein the mass ratio of the content of phosphatidyl inositol or the salt thereof (B) in terms of phosphatidyl inositol content to the content of sphingomyelin (A) in the solid supplement, i.e., [(B)/(A)], is from 0.05 to 3.

Abstract: A solid supplement comprising the following components (A) and (B): (A) sphingomyelin in an amount of from 0.15 to 7% by mass; and (B) phosphatidyl inositol or a salt thereof, wherein the mass ratio of the content of phosphatidyl inositol or the salt thereof (B) in terms of phosphatidyl inositol content to the content of sphingomyelin (A) in the solid supplement, i.e., [(B)/(A)], is from 0.05 to 3.

Abstract: An optical element holding apparatus includes an annular vibration attenuation plate, which covers a peripheral portion of a lens, and a connection member, which is formed of a damping alloy and which fixes the vibration attenuation plate to a frame body in a state of non-contact with the surface of the lens. The vibration attenuation plate and nitrogen gas in a clearance between the vibration attenuation plate and the surface of the lens form a squeeze film damper.

Abstract: An optical element holding apparatus includes an annular vibration attenuation plate, which covers a peripheral portion of a lens, and a connection member, which is formed of a damping alloy and which fixes the vibration attenuation plate to a frame body in a state of non-contact with the surface of the lens. The vibration attenuation plate and nitrogen gas in a clearance between the vibration attenuation plate and the surface of the lens form a squeeze film damper.

Abstract: An optical element holding apparatus includes an annular vibration attenuation plate, which covers a peripheral portion of a lens, and a connection member, which is formed of a damping alloy and which fixes the vibration attenuation plate to a frame body in a state of non-contact with the surface of the lens. The vibration attenuation plate and nitrogen gas in a clearance between the vibration attenuation plate and the surface of the lens form a squeeze film damper.

Abstract: An optical element holding apparatus includes an annular vibration attenuation plate, which covers a peripheral portion of a lens, and a connection member, which is formed of a damping alloy and which fixes the vibration attenuation plate to a frame body in a state of non-contact with the surface of the lens. The vibration attenuation plate and nitrogen gas in a clearance between the vibration attenuation plate and the surface of the lens form a squeeze film damper.

Abstract: A blood fluidity-improving agent, a blood circulation promoter or a cerebrovascular disease-improving agent, containing as an active ingredient thereof one or more ingredients selected from the group consisting of chlorogenic acids, caffeic acids, ferulic acids and pharmaceutically acceptable salts of these acids. The present blood fluidity-improving agent, blood circulation promoter or cerebrovascular disease-improving agent is highly safe and can be orally taken over longer periods of time.

Abstract: Voltage V2 is calculated by subtracting a terminal voltage at an end of discharge F. V. and a voltage drop (Rn+Rpolsat)*Ip caused by a maximum internal resistance (Rn+Rpolsat) of a battery at a given time. A quotient is calculated by dividing V2 by terminal voltage drop V1 after all charged capacity SOC2 (Ah) of a given battery is fully discharged. A dischargeable capacity (Ah) is calculated by multiplying the quotient by a given charged capacity SOC2 (Ah).

Abstract: The present invention provides a method of measuring an intrinsic resistance of a battery at a low rate discharge and an apparatus of the same.

Abstract: A method and apparatus for judging deterioration of a battery are provided, thereby a correct judgement for the deterioration of the battery can be timely carried out so as to replace the battery with another if it is necessary.

Abstract: [PROBLEM] To provide a method and an apparatus for estimating saturated polarization voltage drops, and a method for estimating residual discharge capacity of the battery in order to measure accurately the state of the battery.

Abstract: A CPU 23a detects a charging efficiency which is a ratio of an electrical quantity to be stored in a battery 13 as electromotive force to an electrical quantity flowed into the battery 13 at any time point from a start of charging to an end of charging of the battery 13 on the basis of a charging current and charging voltage obtained by using a current sensor 15 and voltage sensor 17. Then, a fully charged state of the battery 13 is detected when the detected charging efficiency can be regarded as zero.

Abstract: A microcomputer 23 monitors the battery condition by detecting a first deterioration degree caused by increase of an internal resistance of a battery 13 and a second deterioration degree caused by inactivation of an activation material in the battery 13 based on outputs of a current sensor 15 and a voltage sensor 17.

Abstract: A unit for estimating voltage drop 23a-1 estimates voltage drop of a battery terminal when maximum current is continuously supplied at high rate discharge. A unit for estimating residual discharge capacity 23a-2 estimates residual discharge capacity of the battery for allowing the maximum current to be continuously supplied to a load by subtracting the undischargeable electric charge calculated from the voltage drop estimated by the unit for estimating voltage drop 23a-1 from the dischargeable charge in any state of charge.

Abstract: The present invention is to provide an equalizing method and an apparatus thereof for preventing unit cells from being over charged and discharged. After an ignition switch is turned off, CPU checks a voltage of a main battery and judges whether the main battery is in a state of equilibrium or not. When the main battery is in the state of equilibrium, the CPU controls a first and second switch groups to equalize voltages of unit cells included in the main battery by repeating a charge transfer from a maximum voltage cell to a minimum voltage cell for a predetermined period of time.

Abstract: A microcomputer 23 monitors a dischargeable capacity corresponding to a value by subtracting a capacity not to be discharged caused by an internal resistance of a battery from a charge capacity of the battery 13 based on outputs of a current sensor 15 and a voltage sensor 17.

Abstract: A microcomputer monitors, on the basis of outputs from a current sensor and voltage sensor, a voltage drop due to an internal resistance when the drop in the terminal voltage due to polarization occurring during the discharge of a battery is saturated, and a dischargeable capacity of the battery corresponding to the value resulting when the saturated voltage drop of the terminal voltage is subtracted from the chargeable capacity of the battery. Such a configuration provide a battery status monitoring device capable of knowing the battery status correctly, a saturation polarization detecting method which is useful to know the charging state of the battery and a dischargeable capacity detecting method.

Abstract: A blood fluidity-improving agent, a blood circulation promoter or a cerebrovascular disease-improving agent, containing as an active ingredient thereof one or more ingredients selected from the group consisting of chlorogenic acids, caffeic acids, ferulic acids and pharmaceutically acceptable salts of these acids. The present blood fluidity-improving agent, blood circulation promoter or cerebrovascular disease-improving agent is highly safe and can be orally taken over longer periods of time.